Advertisement
Pharmaceutical Companies
Subscribe to Pharmaceutical Companies

The Lead

Halozyme, Ventana enter development agreement

May 27, 2015 10:43 am | by PRNewswire | News | Comments

Under the agreement, Ventana will develop an in vitro diagnostic using Halozyme's proprietary HA binding protein, with the intent of submitting it for regulatory approval. The target will be metastatic pancreatic cancer patients.

Novartis offers pipeline update

May 27, 2015 10:32 am | by PRNewswire | News | Comments

Data will demonstrate advances in research in a variety of cancer types, including melanoma,...

Endo’s Purchase of Par Pharma Shakes up the Industry

May 21, 2015 11:03 am | News | Comments

US Pharma M&A activity has yet to show any signs of a slowdown after the $8.1bn exit of Par...

Novartis Investigational Drug Significantly Improved Lung Function

May 20, 2015 12:02 pm | by PR Newswire | News | Comments

Today, Novartis announced for the first time detailed results from its phase III EXPEDITION...

View Sample

FREE Email Newsletter

J&J Pharmaceuticals Announces 10 filings for Blockbuster Drugs by 2019

May 20, 2015 10:43 am | News | Comments

At a meeting today with analysts, Johnson & Johnson's Janssen Pharmaceuticals announced plans for regulatory approval of more than 10 new drugs between 2015 and 2019, each with the potential to generate at least $1B in sales, in addition to ...

Pfizer Trying To Overcome Patent Cliff

May 20, 2015 10:33 am | News | Comments

Pfizer Inc. is trying to overcome the patent cliff that has seen its recent quarter results suffer by adopting its classic strategy of forging marketing alliances and making acquisitions. The pharma giant recently agreed to buy a stake in Dutch biotechnology company AM-Pharma....

Investigational Hep C Drugs Receive Breakthrough Therapy Designation

May 20, 2015 10:20 am | by Business Wire | News | Comments

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration (FDA) has amended a previously granted Breakthrough Therapy Designation for the investigational daclatasvir and sofosbuvir combination for use in hepatitis C (HCV) patients.

Advertisement

J&J Settles $7.8 Million Lawsuit

May 19, 2015 10:35 am | by AP | News | Comments

Three years ago a jury found that a subsidiary, Janssen Pharmaceutical, committed Medicaid fraud and violated a state law in its labeling and marketing of Risperdal. A $1.2 billion fine was initially imposed on Johnson & Johnson.

Eagle Pharmaceuticals Receives Patent for Rapid Infusion Product

May 19, 2015 8:59 am | by Business Wire | Teva Pharmaceuticals Usa | News | Comments

Eagle Pharmaceuticals, Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. Patent No. 9,034,908, which pertains to the use of the bendamustine hydrochloride (HCl) formulation administered in a 50mL bag within ten minutes.

FTC Seeks More Info From Pfizer About Hospira Acquisition

May 15, 2015 12:04 pm | by Pfizer Inc. | News | Comments

Pfizer Inc. today announced that it has received a request for additional information from the FTC with respect to its previously announced proposed acquisition of Hospira.

Dyadic International Q1 Results

May 15, 2015 11:59 am | by Dyadic International | News | Comments

Dyadic International, Inc. is a global biotechnology company focused on enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries.

Eli Lilly, Sanford-Burnham Announce Collaboration

May 14, 2015 12:00 pm | by Eli Lilly and Company | News | Comments

Eli Lilly and Company and Sanford-Burnham Medical Research Institute today announced that they will collaborate to discover and develop immunological therapies.

Advertisement

ANI Acquires Rights to Testosterone Gel 1%

May 13, 2015 11:31 am | by ANI Pharmaceuticals | News | Comments

ANI Pharmaceuticals has acquired the approved new drug application ("NDA") for a testosterone gel 1% product previously licensed to Teva Pharmaceuticals.

Pfizer Acquires Minority Interest in AM-Pharma

May 12, 2015 11:41 am | by Pfizer | News | Comments

Pfizer recently announced their acquisition of a minority equity interest in AM-Pharma, and secured an exclusive option to acquire the remaining equity in the company.

Endo Acquires Portfolio of Branded and Generic Products

May 11, 2015 11:06 am | by Endo International | News | Comments

Endo International has acquired a broad portfolio of branded and generic injectable and established products focused on pain, anti-infectives, cardiovascular and other specialty therapeutics areas.

Global Hemophilia Therapeutics Market Surges

May 11, 2015 10:42 am | by Frost & Sullivan | News | Comments

New analysis finds that the market could reach $13.4 billion in 2019, due in part to advanced diagnosis capabilities.

BASF Sells Part of Its Pharma Business

May 11, 2015 10:20 am | by Andy Szal, Digital Reporter | News | Comments

BASF recently announced plans to sell several prominent pharmaceutical ingredients to Siegfried Holding AG for $306 million.

Advertisement

California Court Sides With Consumers in Generic Drug Fight

May 8, 2015 11:48 am | by Sudhin Thanawala, Associated Press | News | Comments

The California Supreme Court ruled that settlement agreements between pharmaceutical companies that keep cheaper, generic drugs off the market may be illegal if they include excessive cash payments.

Pharmaceuticals, Life Sciences Show Dramatic Jump in Merger Activity

May 8, 2015 11:15 am | by Andy Szal, Digital Reporter | News | Comments

The pharmaceuticals and life sciences sectors saw 35 mergers and acquisitions worth $166.3 billion in the first three months of 2015, a value that eclipsed transactions from all of 2014.

Mylan Launches Generic Seasonale Tablets

May 7, 2015 11:50 am | by Mylan N.V. | News | Comments

Mylan N.V. today announced the U.S. launch of Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.15 mg/0.03 mg, which is the generic version of Teva's Seasonale Tablets.

J&J Seeks Bioethics Advice on Compassionate Use of Drugs

May 7, 2015 11:39 am | by Lauran Neergaard, AP Medical Writer | News | Comments

Now drug giant Johnson & Johnson is taking an unusual step, turning to independent bioethicists for advice.

Eli Lilly to Build Drug Delivery Innovation Center

May 6, 2015 11:20 am | by Eli Lilly | News | Comments

Eli Lilly and Company today announced plans to establish a new drug delivery and device innovation center in Cambridge, Massachusetts.

Teva Announces Adrucil Recall

May 5, 2015 11:44 am | News | Comments

Teva announced a voluntary recall of eight lots of Adrucil (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) due to the potential presence of particulate matter.

Medicare Contrast in Generic, Brand Prescribing

May 4, 2015 11:21 am | by Lauran Neergaard, AP Medical Writer | News | Comments

The most-used medicines in Medicare's prescription drug program are generics, but the program spends the most on brand-name drugs, led by the heartburn treatment Nexium.

Innate Pharma and AstraZeneca Announce Global Agreement

April 30, 2015 10:53 am | by Innate Pharma SA | News | Comments

Innate Pharma SA today announced that it has signed a co-development and commercialization agreement with AstraZeneca to accelerate and broaden the development of Innate Pharma's proprietary anti-NKG2A antibody.

FDA Approves First Generic Abilify

April 29, 2015 11:22 am | by FDA | News | Comments

The U.S. Food and Drug Administration today approved the first generic versions of Abilify (aripiprazole).

Mylan Raises Offer To Acquire Perrigo

April 29, 2015 11:08 am | by Mylan | News | Comments

Mylan N.V. today announced that it has increased its offer to acquire the issued and to be issued shares of Perrigo.

Merck Hurdles Wall Street Forecasts

April 28, 2015 5:02 pm | by LINDA A. JOHNSON, AP Business Writer | News | Comments

Merck easily beat Wall Street expectations despite first-quarter profit plunging 44 percent. The company was hurt by the sale of its consumer health business, unfavorable currency exchange rates and competition to some drugs.

Bristol-Myers Squibb Reports First Quarter Financial Results

April 28, 2015 11:19 am | by Business Wire | News | Comments

Bristol-Myers Squibb reported results for the first quarter of 2015, which were highlighted by strong global sales for key brands, important regulatory and clinical milestones and the completion of several strategic transactions.

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading